tag value-based-healthcare 
pharmaphorum
OCTOBER 3, 2022
Currently, the ALS drug is priced about five times higher than the top of a value-based range. Following news of Relyvrio’s $158,000 annual price tag, both ALS advocates and outside observers have voiced outrage at the cost. The post Amylyx ALS drug draws criticism over $158,000 price tag appeared first on.
Pharmaceutical Technology
APRIL 13, 2023
Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). If approved, exa-cel would be the first FDA-approved gene therapy based on CRISPR editing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Viseven
NOVEMBER 30, 2022
Jay Rabheru , Head of Marketing, Agency Services, Life Science and Healthcare,? Dr. Geetha Thiagarajan , CTO Lifesciences and Healthcare business unit,? We see many opportunities across the value chain. Now with the pandemic, the whole access to the healthcare ecosystem was limited or even blocked. What does it mean??.
pharmaphorum
JANUARY 31, 2023
This ultimately impacts patient perception of healthcare services in general. Given the high price tags placed on many medications, it’s easy to understand why patients often feel that they are being taken advantage of. In this future, everyone wins – patients, pharma companies, physicians, and the overall healthcare ecosystem.
Pharmaceutical Technology
MARCH 22, 2023
The pharmaceutical industry began using radio frequency identification (RFID) tags in the early 2000s. Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. Twenty years ago, the cost of implementing RFID tags and the ecosystem (software) was much more expensive than today.
pharmaphorum
DECEMBER 2, 2020
As a consequence of Pfizer’s innovation, the price of citric acid tumbled over the succeeding decades, with the value of the chemical falling by 5/6ths in 20 years. The 1990s and 2000s would soon take this blockbuster-based success to new levels. This did not stymie Pfizer’s desire to move its HQ out of the US, though.
pharmaphorum
NOVEMBER 16, 2022
While this is of tremendous benefit to patients, it provides a headache to the pharma industry and to healthcare systems. Yet, in the space of a decade, certain treatments have come along that have raised important questions over the future of treatment, reimbursement, and the value of the quality of life for patients. At more than $2.1
Expert insights. Personalized for you.
52 
Let's personalize your content